PubMed Health⌕ Search

Biomedical subjects

M Worwood

Publications and source records attributed to M Worwood.

At least 19 recordsLinked to original sources
PubMed1991

Luminol peroxidation catalyzed by human isoferritins.

The role of ferritin in catalyzing the oxidation of luminol with the production of chemiluminescence was investigated. The effect of pH was compared to its effect on K3Fe(CN)6-catalyzed oxidation and different pH optima were recorded for the two catalysts. The ferrous iron chelator, bipyridyl, enhanced the production of chemiluminescence catalyzed by FeSO4 and ferritin but had little effect on the K3Fe(CN)6-catalyzed reaction. Desferal reduced the level of chemiluminescence in the presence of FeSO4 and ferritin but was a much more effective inhibitor of chemiluminescence catalyzed by K3Fe(CN)6. The hydroxyl radical scavenger, mannitol, had little effect upon light production whereas superoxide dismutase inhibited light production. The addition of antihuman spleen ferritin completely inhibited activity. The catalytic activity of both H and L rich ferritins was affected by iron content. Activity increased until the Fe/protein ratio reached 0.04 micrograms Fe/micrograms protein and then decreased with increasing iron content. Thus activity is controlled by the iron content of the molecule and influenced by its subunit composition as is the uptake of iron into ferritin. These findings suggest that ferroxidation by ferritin is associated with the ability to generate radicals of the nitrogenous base luminol with the production of chemiluminescence. Although activity is greatest at alkaline pH there is significant activity at pH 7.4. Ferritin therefore may be able to generate free radical reactions in vivo with the acidic isoferritin being most active.

2,2'-Dipyridyl↗
PubMed1991

Stable lyophilized reagents for the serum ferritin assay.

Two monoclonal antibodies to human ferritin, including one that was coupled to horseradish peroxidase, were lyophilized. These reagents show little loss of activity on reconstitution and demonstrate acceptable stability in the accelerated degradation test. When applied in a simple ELISA for the assay of serum ferritin along with the WHO standard for serum ferritin (80/602) they provide a robust assay with standardized reagents which is potentially suitable for use as a reference assay.

Antibodies, Monoclonal↗
PubMed1991

Immunological properties of ferritin during in vitro maturation of human monocytes.

Ferritin in macrophages from human liver and spleen is rich in L subunits but, in the peripheral blood monocytes from which tissue macrophages are derived, the ferritin contains a high proportion of H subunits. We have studied the maturation of monocytes in vitro and the immunological properties of cellular ferritin during this process. Mononuclear cells were isolated from peripheral blood of normal subjects and patients with idiopathic haemochromatosis. Monocytes were obtained by incubation on plastic. The adherent cells were incubated in medium with or without added iron (ferric ammonium citrate) for 20 hours and harvested. Monocytes were also incubated for 7 days before incubation with iron. Ferritin concentrations were determined using immunoassays specific for H and L rich isoferritins. Freshly isolated monocytes were found to have similar concentrations of H- and L-rich isoferritins. Incubation with iron caused an increase in both H- and L-type ferritins. After incubation for 7 d the ferritin present in the normal cell lysates was L-rich and incubation with iron caused accumulation of L-, but not H-type ferritin. Maturation of monocytes is thus associated with the loss of H-rich isoferritins. There were no differences between normal subjects and patients with idiopathic haemochromatosis in ferritin concentrations. In vitro maturation provides an excellent model for studying the developmental control of ferritin synthesis and breakdown.

Adult↗
PubMed1990

Ferritin.

The iron storage protein ferritin is found in all cells of the body as multiple isoferritins composed of 24 sub units of two types. The structure is well understood from increasingly detailed analysis by X-ray crystallography. Genes for the principal subunits (called H and L) have been cloned and are located on chromosomes 11q and 19q respectively. The production of H24 and L24 recombinant molecules is making it possible to explore the relationship between structure and function. The control of ferritin synthesis by iron at the level of translation is providing a model for understanding the control of protein synthesis. H-rich isoferritins are of considerable interest in haematology as they appear to be implicated in control of haemopoiesis and development of malignancy. Whether or not an abnormality in ferritin is the cause of hereditary haemochromatosis is not yet resolved.

Animals↗
PubMed1990

Molecular biology and leukaemia diagnosis.

The diagnosis and classification of leukaemia started with simple morphological examination and now embraces use of special stains, cytochemistry and immunophenotyping. Genetic studies have progressed from karyotyping to detection of genetic changes within genes. The methods described in this chapter are still at an early stage of development and, so far, have provided relatively little in the way of an extension of available diagnostic information. Sometimes the methods provide extensions to existing techniques, for example by the detection of bcr rearrangements in patients who have CML or ALL but do not have a detectable Philadelphia chromosome. Another example is retrospective diagnosis of gene rearrangements using DNA from slide preparations. However, it should be noted that it has only very recently been shown that there is likely to be a causal relationship between the Ph chromosome and leukaemia. Daley et al (1990) induced CML in mice by bone marrow transplantation of cells infected with a retrovirus encoding P210bcr/abl and Heisterkamp et al (1990) produced mice transgenic for a BCR/ABL P190 DNA construct and showed that the progeny died of acute leukaemia (mostly ALL). We have not summarized studies of the incidence of activated oncogenes such as RAS in leukaemia and myelodysplasia. Such oncogenes appear to be involved in many tumours and may well indicate either a predisposition to cancer or a particular stage of malignancy, but their analysis does not at present help in making a diagnosis. It is likely that, as we understand more about the nature of the malignant process, we shall be able to use genetic techniques to enhance considerably both diagnostic and prognostic precision.

DNA↗
PubMed1990

FMS mutations in myelodysplastic, leukemic, and normal subjects.

The FMS gene encodes the functional cell surface receptor for colony-stimulating factor 1, the macrophage- and monocyte-specific growth factor. Codons 969 and 301 have been identified as potentially involved in promoting the transforming activity of FMS. Mutations at codon 301 are believed to lead to neoplastic transformation by ligand independence and constitutive tyrosine kinase activity of the receptor. The tyrosine residue at codon 969 has been shown to be involved in a negative regulatory activity, which is disrupted by amino acid substitutions. This study reports on the frequency of point mutations at these codons, in vivo, in human myeloid malignancies and in normal subjects. We studied 110 patients [67 with myelodysplasia (MDS) and 48 with acute myeloblastic leukemia (AML)], 5 patients being studied at the MDS and the later AML stage of the disease. There was a total incidence of 12.7% (14/110) with mutations in codon 969 and 1.8% (2/110) with mutations in codon 301. Two patients had mutations in the AML stage of the disease but not in the preceding MDS and one had a mutation in the MDS stage but not upon transformation of AML. This is consistent with the somatic origin of these mutations. FMS mutations were most prevalent (20%) in chronic myelomonocytic leukemia and AML type M4 (23%), both of which are characterized by monocytic differentiation. One of 51 normal subjects had a constitutional codon 969 mutation, which may represent a marker for predisposition to myeloid malignancy.

Anemia↗
PubMed1989

An overview of iron metabolism at a molecular level.

Over the last 10 years there has been steady progress in our understanding of the structure of the iron-binding proteins transferrin and ferritin, and the transferrin receptor. In the last few years there have been very rapid developments in understanding of the genetics of these proteins and the regulation of synthesis. This review includes a description of gene localization and structure, the regulation of protein synthesis and the structure of proteins of the transferrin family, the transferrin receptor and the iron storage protein ferritin.

Ferritins↗
PubMed1988

HLA class I and H ferritin gene polymorphisms in normal subjects and patients with haemochromatosis.

The gene for idiopathic haemochromatosis is located on the short arm of chromosome 6 within 1 cM of the HLA-A locus. In this region there are many HLA class I genes, and there may also be a gene for the 'H' subunit of ferritin. Both HLA class I and H ferritin genes are therefore candidates for the abnormal gene in idiopathic haemochromatosis. In 15 unrelated patients the frequency of HLA-A3 was 80% compared with 24% for 600 unrelated individuals from South Wales. The most common haplotype involved is probably HLA-A3, B7. DNA was prepared from leucocytes from 12 of these patients and from 85 normal subjects. After digestion with Taq1, electrophoresis, and Southern blotting, class I sequences were detected by hybridisation to an HLA class I probe (pHLA-A). Of the 34 restriction fragments detected, 22 were polymorphic. Particular fragments correlated with the presence of HLA-A antigens A1, 2, 3, 10, 11, w19, and 28, but there was little correlation with B antigens. Restriction fragment patterns specific for haemochromatosis were not found with TaqI or during less extensive studies with other restriction enzymes. No differences in restriction fragment patterns were found between four patients and four normal subjects apparently homozygous for HLA-A3 and B7. Examination of Southern blotting patterns for genomic DNA from patients and normal subjects with a panel of 12 restriction enzymes and a probe for the H ferritin gene (pDBR-2) revealed no polymorphisms associated with either idiopathic haemochromatosis or particular HLA phenotypes. These studies provide no support for either HLA class I genes or the H ferritin gene as candidates for the haemochromatosis gene.

DNA Restriction Enzymes↗
PubMed1988

The Ha-ras polymorphism in myelodysplasia and acute myeloid leukaemia.

We have assessed the possibility that rare allelic variants of the c-Ha-ras-1 locus may be linked to a susceptibility to malignancy [1]. c-Ha-ras-1 genotypes were scored in 41 patients with myelodysplasia (MDS), 51 patients with acute myeloid leukaemia (AML) and 52 normal subjects. The incidence of rare alleles in the MDS patients was 4.8% and in AML an incidence of 15.7% was found. No rare alleles were found in the normal subjects. We conclude that rare alleles in MDS are not a common predisposing factor.

Alleles↗
PubMed1979

Binding of human serum ferritin to concanavalin A.

1. A high proportion of the ferritin in normal serum binds to concanavalin A. Binding is prevented by the addition of alpha-D-methylglucoside to the reaction mixture. 2. Ferritin in extracts of normal heart, liver and spleen or serum ferritin from patients with massive hepatic necrosis does not bind to concanavalin A. 3. Isoelectric focusing of preparations of serum ferritin from patients with primary haemochromatosis shows that the ferritin fraction binding to concanavalin A consists, predominantly, of the more acidic isoferritins. 4. These findings suggest that carbohydrate residues may be added to ferritin during its secretion into the plasma. Glycosylation may account for the heterogeneity of serum ferritin on isoelectric focusing. 5. Direct release of intracellular ferritin from damaged tissue may be indicated by an increase in the proportion of circulating ferritin which does not bind to concanavalin A. Such an increase has been found in sera from patients with iron overload.

Concanavalin A↗
PubMed1979

Variability of serum ferritin concentration in normal subjects.

Serum ferritin concentrations were measured in normal subjects over periods of 1 day, 1 week and 7 weeks. The variation of the results was compared with variation of control of control sera. In most of the subjects the variation in the results could be attributed to the variation in the method of measurement. No diurnal variation in serum ferritin concentration was observed.

Circadian Rhythm↗
PubMed1979

Serum ferritin.

(1) Brief introduction to iron metabolism and the biochemistry of ferritin. (2) Early studies of circulating ferritin. (3) Methods for measuring serum ferritin concentrations -- immunoradiometric, radioimmuno- and enzyme-linked immuno assays based on liver or spleen ferritin -- an evaluation of these techniques. (4) Serum ferritin concentrations in normal subjects -- definition of normality -- relationship between storage iron and serum ferritin concentrations -- changes during development from birth to old age -- iron deficiency -- variability of serum ferritin concentration -- evaluation of use of ferritin assay for assessment of storage iron levels. (5) Serum ferritin concentrations in disease -- hemochromatosis -- secondary iron overload -- liver damage -- infection and chronic disease -- cancer. (6) Assay of serum ferritin with antibodies to ferritins other than liver or spleen -- ferritinemia and cancer. (7) Properties of serum ferritin -- molecular weight -- iron content -- isoelectric focusing patterns -- carbohydrate content -- immunological properties. (8) Physiology of circulating ferritin -- release of ferritin from tissues -- origin of circulating ferritin -- clearance from the plasma -- iron and protein turnover. (9) Summary -- factors influencing serum ferritin concentrations and clinical use of ferritin estimations.

Adolescent↗